A prospective observational study evaluating c-MET expression and EGFR gene mutation correlation with erlotinib response in second line treatment for advanced/metastatic non-small cell lung cancer patients

被引：0
|
作者：
Park, Cheol-Kyu
Choi, Yoo-Duk
Oh, In-Jae
Lee, Jung-Eun
Lee, Shin Yup
Jang, Tae-Won
Ryu, Jeong-Seon
Kim, Young-Chul
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2773
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
    Duan, Jianchun
    Yang, Xiaodan
    Zhao, Jun
    Zhuo, Minglei
    Wang, Zhijie
    An, Tongtong
    Bai, Hua
    Wang, Jie
    ONCOTARGET, 2018, 9 (02) : 2660 - 2667
  • [22] Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
    Gao, H-F.
    Wu, Y-L.
    Yang, J-J.
    Zhang, X-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S125 - S125
  • [23] ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY
    Hernandez, Alba
    Calera, Lourdes
    Alvarez, Maria
    Hernando, Jorge
    Torres, Irene
    Pajares, Isabel
    Madani, Julia
    Cebollero, Ana
    Anton-Torres, Antonio
    Artal, Angel
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1017 - S1017
  • [24] Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan
    Hsia, T.
    Chang, G.
    Chen, Y.
    Lin, M.
    Su, W.
    Tsai, C.
    Tsai, C.
    Yang, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 375 - 375
  • [25] Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation.
    Lou, Na Na
    Wu, Yi-Long
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Su, Jian
    Chen, Hua-Jun
    Wang, Zhen
    Bai, Xiao-Yan
    Wang, Bin-Chao
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] FINAL RESULTS OF A JAPANESE PHASE 1 TRIAL EVALUATING A C-MET INHIBITOR TIVANTINIB IN COMBINATION WITH AN EGFR INHIBITOR ERLOTINIB IN ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (ARQ 197-003/005 STUDY)
    Yamamoto, N.
    Murakami, H.
    Takahashi, T.
    Hayashi, H.
    Fujisaka, Y.
    Hirashima, T.
    Takeda, K.
    Satouchi, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 424 - 424
  • [27] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [28] EGFR GENE MUTATION IN ADVANCED NON-SMALL CELL LUNG CANCER - A CASE SERIES
    Mehmood, T.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S10 - S10
  • [29] The Impact of C-Met Expression on the Immune Microenvironment and Survival in Locally Advanced Non-Small Cell Lung Cancer
    Xu, Xu.
    Xu, X.
    Zhu, Y.
    Ye, L.
    Zhang, Y.
    Zhang, W.
    Wu, L.
    Wu, C.
    Xu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S566 - S566
  • [30] EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND CORRELATION WITH SENSITIVITY TO ERLOTINIB
    Ricciardi, S.
    Tedesco, B.
    Migliorino, M. R.
    Graziano, P.
    Leone, A.
    Di Salvia, M.
    Capodaglio, V.
    Condo, S.
    De Santis, S.
    De Marinis, F.
    EJC SUPPLEMENTS, 2008, 6 (14): : 134 - 134
12345